echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > New ideas for the treatment of the "king of cancer", innovative therapies to attack the "accomplices" of cancer cells

    New ideas for the treatment of the "king of cancer", innovative therapies to attack the "accomplices" of cancer cells

    • Last Update: 2021-05-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    ▎Editor of WuXi AppTec's content team "In the past 40 years, the survival time of pancreatic cancer patients has been very limited.
    If there is no improvement, it is estimated that by 2025, it will become the second leading cause of death in the world.

    " Xinnan Professor Phoebe Phillips from the University of New South Wales said.

    Because it is difficult to treat and has a high fatality rate, pancreatic cancer has also won the title of "Cancer King".

    An important reason why it is difficult to treat is that the tumor is surrounded by very dense fibrotic tissue.
    The "accomplices" of these cancer cells not only prevent the delivery of chemotherapy drugs into the tumor like a castle, but also secrete factors that promote the proliferation of cancer cells.
    , To further promote the growth of tumors.

    In the past, the treatment methods mainly aimed at cancer cells often failed to achieve the expected results.

    In a study published in Cancer Research recently, scientists discovered an innovative strategy that simultaneously targets pancreatic cancer cells and "accomplice" cells.

    By targeting a transporter called SLC7A11, they can reduce the fibrotic tissue surrounding pancreatic cancer and reduce the size of the tumor, achieving the effect of "two birds with one stone".

    Research on the tumor tissues of patients with pancreatic cancer found that in pancreatic cancer cells and cancer associated fibroblasts (CAF) around the tumor, the expression level of SLC7A11 has an important relationship with the survival of patients.

    If the expression level of SLC7A11 is high, the patient's survival time is relatively low.

    One of the main functions of SLC7A11 is to transport cystine, which plays an important role in supporting the protein synthesis of cancer cells and the synthesis of antioxidants.

    ▲Cancer-associated fibroblasts expressing SLC7A11 in human pancreatic cancer tissues (yellow, picture source: Credit, UNSW Sydney) Then, if the expression of SLC7A11 is reduced, can it disrupt the interaction between pancreatic cancer cells and CAF to achieve What is the effect of shrinking tumors? Researchers designed a siRNA that can effectively reduce SLC7A11.
    They found that siRNA that reduces SLC7A11 expression has multiple effects: it not only reduces the proliferation of CAF, but also makes pancreatic cancer cells more resistant to oxidative stress and iron death (ferroptosis).
    As sensitive.

    Whether it is a three-dimensional tumor model of pancreatic cancer cultured in vitro or a transgenic mouse model of pancreatic cancer, reducing or knocking out the expression of SLC7A11 can reduce the size of the tumor.

    ▲SLC7A11-targeted siRNA as a single agent or in combination with taxane can significantly reduce tumor volume (picture source: reference [1]) "Our strategy can attack tumor cells and their'accomplices' at the same time, so It is an ideal choice for overcoming the aggressiveness and drug resistance of pancreatic cancer.

    " said Professor Phoebe Phillips, the corresponding author of this study.

    What's more gratifying is that, based on this discovery, researchers have found a drug that has been approved for marketing.

    It is called sulfasalazine (sulfasalazine), which is a medicine used to treat rheumatoid arthritis.

    Because it has been approved, it can enter the clinical trial phase more quickly.

    "We know that it can strongly inhibit SLC7A11.
    We will launch clinical trials to test its efficacy in pancreatic cancer patients whose tumors express high levels of SLC7A11.

    More than half of pancreatic cancer patients belong to this type.
    This therapy has improved patient response and The potential for survival.

    "Professor Phoebe Phillips said, "Now is the most optimistic and hopeful time of my career.

    Reference: [1] Sharbeen et al.
    , (2021).
    Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma determine response to SLC7A11 inhibition.
    Cancer Research, DOI: 10.
    1158/0008-5472.
    CAN-20-2496[2] Scientists show how to attack the'fortress' surrounding pancreatic cancer tumors.
    Retrieved May 13, 2021, from Note: This article aims to introduce medical health research Progress is not a treatment plan recommendation.

    If you need treatment plan guidance, please go to a regular hospital for treatment.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.